GET DAILY SIGNALSVeeva Systems (VEEV) Reports +16% Revenue Growth in Fiscal 2027 First Quarter
Key Takeaways
- Veeva Systems reported total revenue of $882.9 million for the fiscal 2027 first quarter ended April 30, 2026, representing 16% year-over-year growth.
- Subscription services revenue reached $730.2 million, up 15% from the prior year.
- Non-GAAP earnings per share came in at $2.24, exceeding analyst expectations of approximately $2.02.
- Non-GAAP operating income totaled $395.4 million, or 45% of total revenue.
- GAAP net income rose 14% year over year to $260.9 million.
- Results surpassed guidance, driven primarily by revenue outperformance in the quarter.
Understanding the Earnings Context
Veeva Systems operates as a leading provider of industry cloud solutions for the global life sciences sector. Its fiscal year ends January 31, making the first quarter the three months ended April 30. The latest results follow a fiscal 2026 full year in which total revenue grew 16% to $3.195 billion. Investors closely monitor these quarterly updates for signs of sustained demand for Veeva’s Vault platform and related services amid evolving regulatory and digital transformation needs in pharmaceuticals and biotechnology.
Breaking Down the Reported Results
Veeva announced fiscal 2027 first-quarter results on June 3, 2026. Total revenue reached $882.9 million, up 16% from $759.0 million in the year-ago quarter. Subscription revenue grew 15% to $730.2 million. GAAP operating income increased 17% to $273.1 million, while non-GAAP operating income rose 13% to $395.4 million. GAAP net income advanced 14% to $260.9 million, and non-GAAP net income grew 13% to $371.1 million. Diluted GAAP earnings per share were $1.57, compared with $1.37 a year earlier, and non-GAAP diluted earnings per share reached $2.24 versus $1.97 previously. The company noted that results exceeded guidance mainly due to stronger-than-expected revenue. I also checked this using Tickeron’s AI Screener to see how VEEV compares to others in the industry.
Market Reaction and Investor Sentiment
Following the June 3 release, investor focus centered on the beat relative to consensus estimates and the company’s forward guidance trajectory. The results reinforced confidence in Veeva’s growth trajectory within the life sciences cloud market, with particular attention paid to subscription revenue momentum and operating leverage.
Forward Outlook and Key Factors to Monitor
Investors will track the company’s guidance for subsequent quarters and the full fiscal year to assess momentum in subscription services and any updates on new product adoption. Key areas include demand signals from biopharmaceutical customers, progress on Vault CRM implementations, and the contribution of AI-related offerings. Cost management, headcount trends, and margin expansion remain important watch points given the company’s emphasis on operating efficiency. Industry dynamics such as regulatory changes and digital transformation spending in life sciences could also influence results. The next earnings release is scheduled for late August 2026. From what I see, these elements will be worth watching closely in the coming months.
Integrating AI Tools into My Research Process
One resource I turn to regularly for screening and comparing opportunities is Tickeron’s AI Screener. It is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. AI Screener
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
VEEV sees MACD Histogram crosses below signal line
VEEV saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 28, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 51 instances where the indicator turned negative. In 34 of the 51 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 67%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for VEEV moved out of overbought territory on October 26, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 35 similar instances where the indicator moved out of overbought territory. In 23 of the 35 cases, the stock moved lower in the following days. This puts the odds of a move lower at 66%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VEEV as a result. In 50 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 64%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VEEV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 41 of 54 cases where VEEV's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
Following a +0.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where VEEV advanced for three days, in 179 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
VEEV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 134 of 210 cases where VEEV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. VEEV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 58 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 71 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.617) is normal, around the industry mean (4.477). P/E Ratio (48.989) is within average values for comparable stocks, (13.414). Projected Growth (PEG Ratio) (1.248) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (12.739) is also within normal values, averaging (6.065).
The Tickeron Profit vs. Risk Rating rating for this company is 96 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VEEV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of industry-specific, cloud-based software solutions for the life sciences industry
Industry ServicestotheHealthIndustry
Advertisement